NasdaqGM - Delayed Quote USD

TransMedics Group, Inc. (TMDX)

92.08 +2.83 (+3.17%)
At close: April 26 at 4:00 PM EDT
92.11 +0.03 (+0.03%)
After hours: April 26 at 7:47 PM EDT
Key Events
Loading Chart for TMDX
DELL
  • Previous Close 89.25
  • Open 90.00
  • Bid 91.92 x 200
  • Ask 92.17 x 100
  • Day's Range 89.99 - 92.90
  • 52 Week Range 36.42 - 99.63
  • Volume 594,489
  • Avg. Volume 741,757
  • Market Cap (intraday) 3.025B
  • Beta (5Y Monthly) 1.98
  • PE Ratio (TTM) --
  • EPS (TTM) -0.77
  • Earnings Date Apr 29, 2024 - May 3, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 99.40

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

www.transmedics.com

584

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TMDX

Performance Overview: TMDX

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TMDX
16.66%
S&P 500
6.92%

1-Year Return

TMDX
10.79%
S&P 500
25.26%

3-Year Return

TMDX
219.94%
S&P 500
22.00%

5-Year Return

TMDX
--
S&P 500
74.80%

Compare To: TMDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TMDX

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    3.02B

  • Enterprise Value

    3.15B

  • Trailing P/E

    --

  • Forward P/E

    250.00

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    12.39

  • Price/Book (mrq)

    22.05

  • Enterprise Value/Revenue

    13.02

  • Enterprise Value/EBITDA

    -408.42

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -10.36%

  • Return on Assets (ttm)

    0.06%

  • Return on Equity (ttm)

    -15.42%

  • Revenue (ttm)

    241.62M

  • Net Income Avi to Common (ttm)

    -25.03M

  • Diluted EPS (ttm)

    -0.77

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    394.81M

  • Total Debt/Equity (mrq)

    376.05%

  • Levered Free Cash Flow (ttm)

    -191.58M

Research Analysis: TMDX

Analyst Price Targets

95.00
99.40 Average
92.08 Current
105.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: TMDX

Fair Value

92.08 Current
 

Dividend Score

0 Low
TMDX
Sector Avg.
100 High
 

Hiring Score

0 Low
TMDX
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
TMDX
Sector Avg.
100 High
 

People Also Watch